• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    4/25/24 4:16:21 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QLI alert in real time by email
    6-K 1 tm2412677d1_6k.htm 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April 2024

     

    Commission File Number: 001-39805

     

    Qilian International Holding Group Ltd

     

    Jiuquan Economic and Technological Development Zone

    Jiuquan City, Gansu Province, 735000

    People’s Republic of China

    +86-0937-2689523

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x Form 40-F ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

      

     

     

     

     

     

     

    Submission of Matters to a Vote of Security Holders.

     

    Qilian International Holding Group Limited (the “Company”) held an extraordinary meeting of shareholders at 9:00 a.m. EST on April 19, 2024 at No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District, Chengdu, PRC. Shareholders of the Company ordinary shares voted by proxy or at the meeting. There were 27,788,572 votes casted, representing approximately 77.73% of the total 35,750,000 outstanding votes and therefore constituting a quorum of more than one third of the shares outstanding and entitled to vote at the meeting as of the record date of March 7, 2024. Each ordinary share is entitled to one vote. The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows:

     

     

    1.The following constitutes the number of votes voted with respect to the approval of the increase of the Company’s authorized share capital, with effect from such date as the board of directors of the Company may determine in its sole discretion, from US$166,667 divided into 100,000,000 ordinary shares of par value US$0.00166667 each (each being an “Ordinary Share”) to US$833,335 divided into 500,000,000 Ordinary Shares of par value US$0.00166667 each (the “Share Capital Increase”).;

     

    For   Against   Abstain
    27,737,265   50,021   1,286

     

    Accordingly, the Share Capital Increase has been approved.

     

    2.The following constitutes the votes with respect to that the approval of, immediately following the Share Capital Increase, the re-designation and re-classification of the Company’s authorized share capital as follows:

     

    (i)       each issued and outstanding Ordinary Share, which is expected to be 35,750,000 Ordinary Shares, be re-designated and re-classified into one Class A ordinary share of par value US$0.00166667 each (each being a “Class A Ordinary Share”);

     

    (ii)       of the remaining authorized but unissued Ordinary Shares:

     

    (a)       50,000,000 Ordinary Shares be re-designated and re-classified into 50,000,000 preferred shares of par value US$0.00166667 each (each being a “Preferred Share”);

    (b)       100,000,000 Ordinary Shares be re-designated and re-classified into 100,000,000 Class B Ordinary Shares of par value US$0.00166667 each; and

    (c)       each of the remaining authorized but unissued Ordinary Shares, which is expected to be 314,250,000 be re-designated and re-classified into Class A Ordinary Shares of par value US$0.00166667 each, (the “Share Capital Reorganization”),

     

    such that following the Share Capital Reorganization, the authorized share capital of the Company shall be US$833,335 divided into 350,000,000 Class A Ordinary Shares of par value US$0.00166667 each, 100,000,000 Class B Ordinary Shares of par value US$0.00166667 each, and 50,000,000 Preferred Shares of par value US$0.00166667 each.

     

    For   Against   Abstain
    27,736,965   49,521   2,086

     

    Accordingly, the Share Capital Reorganization has been approved.

     

    3.The following constitutes the votes with respect to the approval and adoption of a third amended and restated memorandum and articles of association (the “Amended MoA”) to effect the Share Capital Increase, the Share Capital Reorganization and typographical corrections if and to the extent each is effected;

     

    For   Against   Abstain
    27,737,039   48,722   2,811

     

    Accordingly, the Amended MoA has been approved and adopted.

     

    The board of directors has unanimously approved that the effective date of the Share Capital Increase, Share Capital Reorganization and the Amended M&A is April 29, 2024.

     

     

     

     

    Home Country Rule Exemption

     

    The Company hereby clarifies the home country rule exemption disclosure to be included in the next Form 20-F for the fiscal year ending September 30, 2024.

     

    Pursuant to the home country rule exemption set forth under Nasdaq Listing Rule 5615, the board of directors of the Company has elected to follow the Company’s home country rules for exemption from the requirements as follows:

     

    (i)Nasdaq Listing Rule 5605(b)(1), which requires that at least a majority of a listed company’s board of directors be independent directors;
    (ii)Nasdaq Rule 5605(b)(2), which requires that independent directors regularly meet in executive sessions where only independent directors are present;
    (iii)Nasdaq Listing Rule 5640, which provides that voting rights of existing shareholders cannot be disparately reduced or restricted through any corporate action or issuance; and
    (iv)Nasdaq Listing Rule 5635, which requires a listed company to obtain shareholder approval for certain dilutive events, including:
    a.certain acquisitions in connection with the acquisition of the stock or assets of another company;
    b.an issuance that will result in a change of control of the company;
    c.the establishment or amendment of certain equity-based compensation plans and arrangements; and
    d.certain transactions other than a public offering involving issuances of a 20% or greater interest in the company.

     

    Other than those described above, there are no significant differences between the Company’s corporate governance practices and those followed by U.S. domestic companies under Nasdaq Capital Market corporate governance listing standards.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: April 25, 2024

     

      QILIAN INTERNATIONAL HOLDING GROUP LTD
         
      By: /s/ Zhanchang Xin
      Name:  Zhanchang Xin
      Title: Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer)

     

     

    Get the next $QLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QLI
    SEC Filings

    View All

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6-K - Qilian International Holding Group Ltd (0001779578) (Filer)

    6/6/24 4:15:24 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6-K - Qilian International Holding Group Ltd (0001779578) (Filer)

    6/4/24 9:25:25 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Qilian International Holding Group Ltd.

    EFFECT - Qilian International Holding Group Ltd (0001779578) (Filer)

    5/17/24 12:15:27 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to "BGM"

    CHENGDU, China, Aug. 13, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that effective on August 11, 2024, its Class A ordinary shares will begin trading on the Nasdaq Capital Market under the ticker symbol "BGM". The new ticker symbol will replace the Company's current ticker symbol "QLI." No action by the Company's shareholders is required with respect to the ticker symbol change. The Company's Class A ordinary shares will continue to be listed on the Nasdaq Capital Market and the CUSIP number remains unchanged. About Qilian International Holding Group L

    8/13/24 8:00:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule

    CHENGDU, China, July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on July 10, 2024, NASDAQ notified the Company that it has determined that for the 10 consecutive business days, from June 21, 2024 to July 9, 2024, the closing bid price of the Company's Class A ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter. About Qilian International Holding Group Ltd Qilian International Holding Group Ltd, headquartered in Gansu, China, is

    7/12/24 8:30:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qilian International Holding Group Limited Announces 1 for 5 Reverse Share Split

    CHENGDU, China, June 18, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced today that an 1 for 5 reverse split of its authorized share capital, was approved by the Company's board of directors on May 29, 2023 and will become effective on June 21, 2024. In connection with the reverse share split, the Company's shareholders will receive one new Class A ordinary share or Class B ordinary share of the Company for every five Class A ordinary shares or every five Class B ordinary shares they hold, respectively. The Company's Class A ordinary shares are expected to begi

    6/18/24 8:30:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLI
    Financials

    Live finance-specific insights

    View All

    Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders

    JIUQUAN, China, Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd ((the ", Company", NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of $0.05 per ordinary share, payable in cash on or about March 6, 2023, to shareholders of record on February 28, 2023. "Despite the impacts of COVID-19 on us in our last fiscal year, the Company maintained decent operating results and healthy cash flow. We expect better financial results as China announced a rollback of its anti-COVID measures." said Mr. Zhanchang Xin, CEO of the Company. About Qilian International Holding Group Ltd Q

    2/16/23 4:30:00 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care